J&J’s Invega to launch in January
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson's antipsychotic Invega (paliperidone extended-release) received FDA approval Dec. 19, and the firm is set to launch the schizophrenia treatment in early January. The follow-on to Risperdal (risperidone) is the first new atypical antipsychotic approved by FDA for schizophrenia since 2003. Approval was based on three six-week, placebo-controlled trials in more than 1,600 patients worldwide. J&J is also conducting two Phase III head-to-head trials of Invega compared to AstraZeneca's Seroquel (quetiapine) in both schizophrenia and bipolar disorder; results are expected in 2007. Invega delivers paliperidone through the Alza OROS extended-release technology, which results in minimal fluctuations in blood level, according to J&J...
You may also be interested in...
J&J Invega, paroxetine interaction data
Johnson & Johnson's schizophrenia therapy Invega (paliperidone) did not produce a drug-drug reaction when administered with the selective serotonin reuptake inhibitor paroxetine (GlaxoSmithKline's Paxil and generics), according to data presented at the American Psychiatric Association annual meeting in San Diego May 22. Sixty male patients were randomized to receive either paliperidone or paroxetine plus paliperidone. Four days after paliperidone administration, no clinically significant increases in paliperidone exposures were seen. "Drug interactions frequently occur in patients with schizophrenia because this population is often treated for multiple medical and psychiatric conditions," Johnson & Johnson Franchise Medical Leader for Psychiatry Joseph Palumbo said. Study results indicate that CYP2D6-inhibiting antidepressants can be administered with paliperidone, he said. Invega, a follow-on to J&J's Risperdal (risperidone), launched in January (1Pharmaceutical Approvals Monthly January 2007, In Brief)...
Invega Review Shows FDAers At Odds Over Safety Issues With Risperdal Follow-On
FDA review documents illustrate internal disagreement at the division level during the agency’s review of Johnson & Johnson’s schizophrenia agent Invega. The review also highlights the difficulty in assessing safety in the unique patient population affected by schizophrenia.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.